Published in Rev Infect Dis on June 24, 1982
Infections caused by Mycobacterium avium complex in immunocompromised patients: diagnosis by blood culture and fecal examination, antimicrobial susceptibility tests, and morphological and seroagglutination characteristics. J Clin Microbiol (1985) 5.22
Comparison of 15 laboratory and patient-derived strains of Mycobacterium avium for ability to infect and multiply in cultured human macrophages. J Clin Microbiol (1986) 2.94
Identification of various serovar strains of Mycobacterium avium complex by using DNA probes specific for Mycobacterium avium and Mycobacterium intracellulare. J Clin Microbiol (1990) 2.73
Geographic distribution, frequency, and specimen source of Mycobacterium avium complex serotypes isolated from patients with acquired immunodeficiency syndrome. J Clin Microbiol (1990) 2.35
Mycobacterial disease, immunosuppression, and acquired immunodeficiency syndrome. Clin Microbiol Rev (1989) 2.20
Mycobacterium avium-M. intracellulare isolates from patients with or without acquired immunodeficiency syndrome. Antimicrob Agents Chemother (1986) 1.79
Clinical and epidemiological importance of typing of Mycobacterium avium complex isolates. J Clin Microbiol (1992) 1.69
Therapeutic efficacy of the benzoxazinorifamycin KRM-1648 against experimental Mycobacterium avium infection induced in rabbits. Antimicrob Agents Chemother (1993) 1.42
Multilocus enzyme electrophoresis analysis of the Mycobacterium avium complex and other mycobacteria. J Clin Microbiol (1991) 1.37
Comprehensive approach to identification of serovars of Mycobacterium avium complex. J Clin Microbiol (1992) 1.14
Serovars of Mycobacterium avium complex isolated from patients in Sweden. J Clin Microbiol (1990) 1.13
Serovars of Mycobacterium avium complex isolated from patients in Denmark. J Clin Microbiol (1994) 1.01
Antibodies to mycobacterial peptidoglycolipid and to crude protein antigens in sera from different categories of human subjects. J Clin Microbiol (1988) 0.90
Arylsulfatase activity for differentiating Mycobacterium avium and Mycobacterium intracellulare. J Clin Microbiol (1990) 0.83
Structural analysis and biosynthesis gene cluster of an antigenic glycopeptidolipid from Mycobacterium intracellulare. J Bacteriol (2008) 0.82
Implications of antibodies to pyruvylated glucose in healthy populations for mycobacterioses and other infectious diseases. J Clin Microbiol (1990) 0.80
Rapid identification of serotypes of Mycobacterium avium-M. intracellulare complex by using infected swine sera and reference antigenic glycolipids. J Clin Microbiol (1989) 0.76
Evaluation of the BACTEC radiometric method for recovery of mycobacteria and drug susceptibility testing of Mycobacterium tuberculosis from acid-fast smear-positive specimens. J Clin Microbiol (1983) 10.49
Infections caused by Mycobacterium avium complex in immunocompromised patients: diagnosis by blood culture and fecal examination, antimicrobial susceptibility tests, and morphological and seroagglutination characteristics. J Clin Microbiol (1985) 5.22
The 7H11 medium for the cultivation of mycobacteria. Am Rev Respir Dis (1968) 4.23
Immunological evaluation of a component isolated from Mycobacterium bovis BCG with a monoclonal antibody to M. bovis BCG. Infect Immun (1984) 3.46
Detection of mycobacteria by radiometric and standard plate procedures. J Clin Microbiol (1983) 2.85
Use of pyrazinamidase activity on Mycobacterium tuberculosis as a rapid method for determination of pyrazinamide susceptibility. Antimicrob Agents Chemother (1981) 2.62
Identification of atypical mycobacteria by thin-layer chromatography of their surface antigens. J Clin Microbiol (1978) 2.40
Isolation of mycobacteria from clinical specimens by use of selective 7H11 medium. Am J Clin Pathol (1976) 1.90
Clinical and epidemiological importance of typing of Mycobacterium avium complex isolates. J Clin Microbiol (1992) 1.69
Universal occurrence of antibodies to tubercle bacilli in sera from non-tuberculous and tuberculous individuals. Clin Exp Immunol (1973) 1.68
Rifampin in the treatment of drug-resistant mycobacterium tuberculosis infections. N Engl J Med (1970) 1.67
Biological properties of alpha-toxin mutants of Staphylococcus aureus. J Bacteriol (1966) 1.56
Enzyme-linked immunosorbent assay of glycolipid antigens for identification of mycobacteria. J Clin Microbiol (1985) 1.51
In vitro susceptibility of mycobacteria to rifampin. Am Rev Respir Dis (1969) 1.51
Shared antigens between heterologous bacterial species. Infect Immun (1972) 1.50
Induction of Resistance by Listeria monocytogenes Cell Wall Fraction. Infect Immun (1974) 1.48
Precipitation of radiolabeled antigen-antibody complexes with protein A-containing Staphylococcus aureus. J Immunol (1977) 1.45
Shared antigens between Mycobacterium bovis (BCG) and other bacterial species. Science (1972) 1.41
Requirement for bone marrow-derived cells in resistance to Listeria. J Immunol (1974) 1.40
Cross-resistance in M. tuberculosis to kanamycin, capreomycin and viomycin. Tubercle (1977) 1.37
Shared antigens between Mycobacterium bovis (BCG) and neoplastic cells. J Natl Cancer Inst (1974) 1.17
Heterogeneity of the stability of messenger ribonucleic acid in Salmonella typhimurium. J Bacteriol (1967) 1.10
Rapid and sensitive identification of Mycobacterium tuberculosis. J Clin Microbiol (1985) 1.09
Genetic recombination between alpha-toxin mutants of Staphylococcus aureus. J Bacteriol (1966) 1.07
Immunological method to differentiate between antigens of tubercle bacilli, other mycobacterial species, and non-acid-fast bacteria. Infect Immun (1978) 1.02
Antigenic Differences Between Mycobacterium bovis Strain BCG and an Isoniazid-Resistant Mutant. Infect Immun (1971) 0.97
Shared antigens between human malignant melanoma cells and Mycobacterium bovis (BCG). J Immunol (1976) 0.93
Mycosides C: behavior as receptor site substance for mycobacteriophage D4. J Virol (1972) 0.93
Urease testing of mycobacteria with BACTEC radiometric instrumentation. J Clin Microbiol (1982) 0.89
Definition of the surface antigens of Mycobacterium malmoense and use in studying the etiology of a form of mycobacteriosis. J Bacteriol (1987) 0.88
The primary interaction of antibody to components of aspergilli. II. Antibodies in sera from normal persons and from patients with aspergillosis. J Allergy Clin Immunol (1972) 0.86
Antimycobacterial activity of some potential chemotherapeutic compounds. Tubercle (1978) 0.84
Prevention of tumor growth after intradermal injection of BCG extracts: a comparison of results in strain-2 guinea pigs from the National Institutes of Health and from the National Jewish Hospital and Research Center. J Natl Cancer Inst (1976) 0.81
Primary interaction between antibody and components of Alternaria. I. Immunology and chemical characteristics of labeled antigens. J Allergy Clin Immunol (1975) 0.81
The primary interaction of antibody to components of aspergilli. I. Immunologic and chemical characteristics of a nonprecipitating antigen. J Allergy Clin Immunol (1972) 0.80
Transmission of BCG-associated tumor resistance from maternal to newborn guinea pigs. J Natl Cancer Inst (1976) 0.79
Niacin, nitrate and pyrazinamide studies using Middlebrook 7H10 Broth. Eur J Clin Microbiol (1984) 0.78
Antibodies to melanoma cell and BCG antigens in sera from tumour-free individuals and from melanoma patients. Nature (1976) 0.77
Suppression and immunotherapy of the guinea pig line-10 hepatocarcinoma mediated by nonviable Staphylococcus aureus. J Natl Cancer Inst (1978) 0.75
X-ray fluorescence spectroscopy of a periapical mass of tooth. J Colo Dent Assoc (1974) 0.75
Immunotherapy of the guinea pig line 10 hepatocarcinoma with a variety of nonviable bacteria. Cancer Res (1980) 0.75
Identification of silver in a periapical lesion of a tooth. Am J Clin Pathol (1973) 0.75
Shared antigens between bacteria and guinea pig line 10 hepatocarcinoma cells. Cancer Res (1976) 0.75
Rifampin in the treatment of drug-resistant TB. Md State Med J (1971) 0.75